Combination of Lurbinectedin and Osimertinib for Treatment of EGFR-Mutated Transformed SCLC: A Brief Report
Year: 2025
Type: article
Study design: Case Report
Abstract: -mutated NSCLC. After an initial response, patients on this therapy ultimately develop resistance leading to disease progression. One of the resistance mechanisms is histological transformation to SCLC. There is no standard of care for the management of transformed SCLC. Given the rarity of transformed SCLC, it is important to study treatment options that are safe and effective for this disease. In this case series, three patients received treatment with lurbinectedin plus osimertinib after transformation to SCLC. In our limited experience, the combination was found to be safe.
Authors: Aditi Singh, Arthi Sridhar, Aastha Poddar, Anastasios Dimou, Kaushal Parikh, Mohamed Shanshal, Anna Schwecke, Nicole Moffett, Manish R. Patel, Aaron S. Mansfield, Konstantinos Leventakos
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,000
OpenAlex ID: W4407463539